文献速递妇科产科

孕激素与维生素D协同抑制输卵管癌变

Progestin and vitamin D synergistically inhibit fallopian tube carcinogenesis.
PubMed 文献 · Gynecol Oncol · 2026-03-12

本研究在mogp-TAg小鼠模型中验证维生素D是否增强孕激素对输卵管癌变的抑制作用。结果显示,在孕激素剂量仅轻度抑制癌变时,联合胆钙化醇协同减少p53印记(CI=0.525)和浆液性输卵管上皮内癌(CI=0.603),并增强降低输卵管癌发生率。体外实验表明联合处理协同抑制p53异常输卵管上皮细胞增殖(CI=0.491-0.858)并诱导凋亡和自噬,且与CYP24A1抑制相关。

要点

  • 孕激素与维生素D联合协同抑制输卵管癌变,效果优于单药。
  • 联合处理协同减少p53印记和浆液性输卵管上皮内癌。
  • 联合处理抑制CYP24A1并诱导p53异常细胞凋亡和自噬。

核心结论

  • 孕激素和维生素D单独均抑制输卵管癌变,但联合作用更强,支持其作为输卵管/卵巢癌化学预防策略的潜力。

研究设计与样本

  • 研究使用5周龄雌性mogp-TAg小鼠,随机分为DMPA、胆钙化醇、DMPA/胆钙化醇联合及溶剂对照四组,处理3、5或7周。
  • 体外使用人原代及p53异常的输卵管上皮细胞系探讨细胞机制。

主要发现

  • 在孕激素剂量仅轻度抑制体内癌变时,联合胆钙化醇协同减少p53印记(Chou-Talalay CI=0.525)和浆液性输卵管上皮内癌(CI=0.603)。
  • 联合处理增强降低输卵管癌发生率。
  • 体外联合处理协同抑制p53异常输卵管上皮细胞系增殖(CI=0.491-0.858),诱导凋亡和自噬,但对正常输卵管上皮细胞无此效应。
  • 联合处理原代和p53异常输卵管上皮细胞显著降低维生素D失活酶CYP24A1。
  • 在联合处理的p53异常输卵管上皮细胞中,凋亡诱导与CYP24A1抑制相关。

临床怎么用

  • 孕激素联合维生素D可能作为输卵管/卵巢癌的化学预防策略,尤其针对p53异常细胞。
  • 联合方案可协同增强抑制癌变,减少单药剂量相关效应。

局限性

  • 研究基于mogp-TAg小鼠模型和体外细胞实验,尚未在人体中验证。
  • 未报告联合方案的最佳剂量、长期安全性及临床转化数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We previously showed that progestins and vitamin D synergistically inhibit ovarian cancer cell viability in vitro, and independently inhibit fallopian tube (FT) carcinogenesis in vivo by clearing p53-altered cells via apoptosis. This study sought to investigate whether vitamin D enhances progestin-mediated inhibition of FT carcinogenesis in the mogp-TAg mouse model and examine the underlying cellular mechanisms. METHODS: Female mogp-TAg mice (5-week-old) were assigned to four treatment groups: progestin-Depo-medroxyprogesterone acetate (DMPA), vitamin D (cholecalciferol, Chole), DMPA/Chole (Combo), or vehicle (DMPA solvent) for 3, 5 or 7 weeks. FT tissues and blood were collected for analysis. Human primary and p53-altered fallopian tube epithelial (FTE) cells were used to examine the cellular mechanisms involved in inhibition of FT carcinogenesis. RESULTS: At doses of progestin that modestly inhibited FT carcinogenesis in vivo, co-treatment with Chole synergistically reduced p53 signatures [Chou-Talalay Combination Index (CI); CI = 0.525], serous tubal intraepithelial carcinoma (CI = 0.603), and enhanced reduction in FT carcinoma incidence. In vitro, Combo treatment synergistically inhibited proliferation (CI = 0.491-0.858) and induced apoptosis and autophagy in p53-altered FTE cell lines, but not in normal FTE cells. Combo treatment of primary and p53-altered FTE cells led to significant reduction in the vitamin D inactivating enzyme CYP24A1. The induction of apoptosis was associated with CYP24A1 inhibition in p53-altered FTE cells in the combination treatment. CONCLUSIONS: Both progestin and vitamin D individually inhibit FT carcinogenesis, but their combination was more potent than each agent alone. These findings support the potential of the combination of progestin and vitamin D as a chemopreventive strategy for fallopian tube/ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Nelson OL, Rosales R, Turbov J, et al. Progestin and vitamin D synergistically inhibit fallopian tube carcinogenesis. Gynecol Oncol. 2026. PMID: 41825096. doi:10.1016/j.ygyno.2026.02.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。